Santen Pharmaceutical Co Stock Shares Owned By Insiders
SNPHF Stock | USD 9.26 0.00 0.00% |
Santen Pharmaceutical Co fundamentals help investors to digest information that contributes to Santen Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Santen Pink Sheet. The fundamental analysis module provides a way to measure Santen Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Santen Pharmaceutical pink sheet.
Santen |
Santen Pharmaceutical Co Company Shares Owned By Insiders Analysis
Santen Pharmaceutical's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Santen Pharmaceutical Shares Owned By Insiders | 3.21 % |
Most of Santen Pharmaceutical's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santen Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 3.207% of Santen Pharmaceutical Co are shares owned by insiders. This is 78.87% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The shares owned by insiders for all United States stocks is 68.22% higher than that of the company.
Santen Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santen Pharmaceutical's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santen Pharmaceutical could also be used in its relative valuation, which is a method of valuing Santen Pharmaceutical by comparing valuation metrics of similar companies.Santen Pharmaceutical is currently under evaluation in shares owned by insiders category among related companies.
Santen Fundamentals
Return On Equity | -0.0264 | |||
Return On Asset | -0.001 | |||
Profit Margin | (0.03) % | |||
Operating Margin | (0) % | |||
Current Valuation | 2.6 B | |||
Shares Outstanding | 388.22 M | |||
Shares Owned By Insiders | 3.21 % | |||
Shares Owned By Institutions | 53.50 % | |||
Price To Earning | 14.54 X | |||
Price To Book | 1.39 X | |||
Price To Sales | 0.01 X | |||
Revenue | 266.26 B | |||
Gross Profit | 156.59 B | |||
EBITDA | 53.91 B | |||
Net Income | 27.22 B | |||
Cash And Equivalents | 69.53 B | |||
Cash Per Share | 176.84 X | |||
Total Debt | 32.93 B | |||
Debt To Equity | 0.1 % | |||
Current Ratio | 2.48 X | |||
Book Value Per Share | 780.63 X | |||
Cash Flow From Operations | 46.04 B | |||
Earnings Per Share | 0.50 X | |||
Price To Earnings To Growth | 20,399 X | |||
Number Of Employees | 4.32 K | |||
Beta | 0.38 | |||
Market Capitalization | 2.95 B | |||
Total Asset | 459.98 B | |||
Retained Earnings | 230.22 B | |||
Working Capital | 106.3 B | |||
Current Asset | 156.63 B | |||
Current Liabilities | 50.32 B | |||
Annual Yield | 0.03 % | |||
Five Year Return | 1.57 % | |||
Net Asset | 459.98 B | |||
Last Dividend Paid | 16.0 |
About Santen Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santen Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santen Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santen Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
CEOs Directory Screen CEOs from public companies around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |